Appeal No. 1996-0682
Application 08/127,121
podophyllotoxin for treating condyloma acuminata. Suffice it
to say that since the effective amount of the active
ingredient for the treatment of psoriasis is substantially the
same as the effective amount of the active ingredient for
treating genital warts (specification, page 2, lines 8-15 and
lines 19-24), this claimed requirement which is directed to
the intended use of the composition does not serve to
differentiate the claimed composition from that of Leander.
Again, see Leander at column 4, lines 27-29. Accordingly, we
also affirm the rejection of appealed claims
31-35.
The decision of the examiner, accordingly, is affirmed.
No time period for taking any subsequent action in
connection with this appeal may be extended under 37 CFR
§ 1.136(a).
AFFIRMED
)
ANDREW H. METZ )
Administrative Patent Judge )
)
)
) BOARD OF PATENT
JOHN D. SMITH )
Administrative Patent Judge ) APPEALS AND
11
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007